Dr. Sakamuri joined Ambrx as Vice President, Head of Chemistry bringing over 20 years of drug discovery experience and leadership in antibody drug conjugates, oligonucleotides, peptides and small molecules. He is an expert in developing novel platform technologies including chemical and enzymatic bioconjugations, oligonucleotide and peptide delivery and phosphate prodrugs.
Prior to joining Ambrx, he co-founded Tollnine Inc. and served as Vice President, Chemistry transitioning Tollnine into a pre-clinical development company. Prior to Tollnine, Dr. Sakamuri served as Executive Director, Head of Chemistry at Solstice Biologics for over five years. As a founding employee he built the Solstice Chemistry Team, invented best-in-class siRNA-GalNAc conjugates for rare and genetic disease programs and represented Solstice in seeking pharma collaborations and venture capital fund raising. Dr. Sakamuri also served as Director of Chemistry at Traversa Therapeutics working on siRNA delivery technology. Dr. Sakamuri worked as a Project Leader at CovX developing CovX-Body technology, invented best-in-class GLP-1R agonist antibody conjugate acquired by Pfizer and completed Phase 1 studies. Dr. Sakamuri previously held roles of increasing responsibility at Orchid Pharmaceuticals and Morphochem leading small molecule drug discovery programs producing pre-clinical compounds in Oncology and Type 2 Diabetes. He was responsible for alliance management with pharma partners and managed CRO services.
Dr. Sakamuri is an author/inventor of over 40 patents and publications, carried out his Postdoctoral research at Georgetown University, Washington DC and holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology, India.